FDA Weighs Lilly, Amgen Findings On Cancer Drugs
The U.S. Food and Drug Administration has asked an advisory committee to consider whether clinical studies by Amgen Inc. and ImClone Systems Inc. are strong enough to show that their respective...To view the full article, register now.
Already a subscriber? Click here to view full article